These data suggest that PIKfyve inhibitors are clinically viable DC-dependent drugs and are promising candidates for novel combination therapy strategies with human-relevant DC-stimulating agents and adjuvants in cancer and other diseases. The gene discussed is PIKFYVE; the disease is cancer.